<code id='F95F5F030F'></code><style id='F95F5F030F'></style>
    • <acronym id='F95F5F030F'></acronym>
      <center id='F95F5F030F'><center id='F95F5F030F'><tfoot id='F95F5F030F'></tfoot></center><abbr id='F95F5F030F'><dir id='F95F5F030F'><tfoot id='F95F5F030F'></tfoot><noframes id='F95F5F030F'>

    • <optgroup id='F95F5F030F'><strike id='F95F5F030F'><sup id='F95F5F030F'></sup></strike><code id='F95F5F030F'></code></optgroup>
        1. <b id='F95F5F030F'><label id='F95F5F030F'><select id='F95F5F030F'><dt id='F95F5F030F'><span id='F95F5F030F'></span></dt></select></label></b><u id='F95F5F030F'></u>
          <i id='F95F5F030F'><strike id='F95F5F030F'><tt id='F95F5F030F'><pre id='F95F5F030F'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:137
          Scanned cerebellum of a mouse brain, affected by Niemann-Pick Type C, shown in pink and teal — biotech coverage from STAT
          The cerebellum of a mouse brain affected by Niemann-Pick Type C. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

          About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients. 

          A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons. 

          advertisement

          NPC has a range of manifestations. When symptoms appear in early childhood, it is often fatal before adulthood. When it manifests  later, it can be milder. But it’s always degenerative and leads to a cluster of challenges: cognitive decline, difficulty with speech and swallowing, enlarged liver, low muscle tone, and, notably, difficulty with balance and muscle control. Researchers and a fervent group of parents were working to develop medicines, but little had yet worked. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          5 takeaways from STAT's examination of Zynex Medical
          5 takeaways from STAT's examination of Zynex Medical

          ApileofZynexMedicalbatteriesandelectrodepadsKayanaSzymczakforSTATSendingpatientsheapsofmedicalsuppli

          read more
          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more

          NIH tests clinical research in primary care with $30 million program

          TheNIH'snewprimarycareresearchnetworkaimstoimproverepresentationinclinicalscience.AdobeFormanyAmeric